Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data

Prelude Therapeutics Inc

2024-Q1 EPS reported -$0.42

Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.
Cash, equivalents & marketable securities $201.9M as of March 31, 2024; cash runway expected into 2026.
PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) on track for initial proof-of-concept data H2 2024.
PRT7732 oral SMARCA2 degrader expected to enter Phase 1 in H2 2024; IND-enabling studies ongoing.
Appointed Sean Brusky as CBO and Robert Doody as SVP, IR in April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prelude Therapeutics Inc reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-053931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.